

Atazanavir Mylan

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IB/0027	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	15/02/2024		SmPC and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



IA/0026/G	This was an application for a group of variations.	11/07/2023	n/a	
	B.III.1.b.2 - Submission of a new/updated or			
	deletion of Ph. Eur. TSE Certificate of Suitability -			
	New certificate for a starting			
	material/reagent/intermediate/or excipient from a			
	new or an already approved manufacturer			
	B.III.1.b.2 - Submission of a new/updated or			
	deletion of Ph. Eur. TSE Certificate of Suitability -			
	New certificate for a starting			
	material/reagent/intermediate/or excipient from a			
	new or an already approved manufacturer			
	B.III.1.b.4 - Submission of a new/updated or			
	deletion of Ph. Eur. TSE Certificate of Suitability -			
	Deletion of certificates (in case multiple certificates			
	exist per material)			
	B.III.1.b.2 - Submission of a new/updated or			
	deletion of Ph. Eur. TSE Certificate of Suitability -			
	New certificate for a starting			
	material/reagent/intermediate/or excipient from a			
	new or an already approved manufacturer			
	B.III.1.b.2 - Submission of a new/updated or			
	deletion of Ph. Eur. TSE Certificate of Suitability -			
	New certificate for a starting			
	material/reagent/intermediate/or excipient from a			
	new or an already approved manufacturer			
	B.III.1.b.2 - Submission of a new/updated or			
	deletion of Ph. Eur. TSE Certificate of Suitability -			
	New certificate for a starting			
	material/reagent/intermediate/or excipient from a			

IA/0023/G	B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer	06/01/2023	n/a	
IA/0022/G	This was an application for a group of variations. B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-	19/12/2022	n/a	

	significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a nonsignificant specification parameter (e.g. deletion of an obsolete parameter) B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a nonsignificant specification parameter (e.g. deletion of an obsolete parameter)				
N/0021	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	22/09/2022		PL	
IB/0020	B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer	01/09/2022	n/a		
N/0019	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	03/02/2022		PL	
Т/0018	Transfer of Marketing Authorisation	12/08/2021	29/09/2021	SmPC, Labelling and PL	

IB/0017/G	This was an application for a group of variations.	29/06/2021	16/07/2021	SmPC and PL
	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH			
R/0016	Renewal of the marketing authorisation.	25/02/2021	26/04/2021	
IA/0015	A.7 - Administrative change - Deletion of manufacturing sites	20/11/2020	29/01/2021	Annex II and PL
IAIN/0014	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	12/03/2020	29/01/2021	Annex II and PL
IB/0013	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by	30/01/2020	29/01/2021	SmPC and PL

	the MAH				
II/0012	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	12/09/2019	n/a		
IAIN/0011/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	10/04/2019	n/a		
IB/0009/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-	28/03/2019	n/a		

IA/0008/G	This was an application for a group of variations.	15/02/2019	n/a	
	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer			
IAIN/0007	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	22/11/2018	21/10/2019	SmPC
IB/0006	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	10/10/2018	21/10/2019	SmPC
IB/0005/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO	06/07/2018	20/09/2018	SmPC and PL

	new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH			
IB/0003/G	This was an application for a group of variations. B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes	03/05/2018	24/05/2018	SmPC, Labelling and PL

	B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes			
IB/0004	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	20/04/2018	24/05/2018	SmPC and PL
IA/0002/G	B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting	23/10/2017	n/a	

	material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer			
IB/0001	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	06/06/2017	24/05/2018	SmPC and PL